Vistagen Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VTGN Nasdaq 8731 https://www.vistagen.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vistagen Therapeutics Inc

Vistagen Announces Stockholder-Approved Reverse Stock Split - Jun 6th, 2023 1:25 pm
Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting - Jun 1st, 2023 12:30 pm
Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting - May 30th, 2023 8:15 pm
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health - May 24th, 2023 12:30 pm
Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference - Apr 19th, 2023 12:30 pm
Vistagen Receives New European Patent for AV-101 - Apr 6th, 2023 12:30 pm
Social Anxiety Disorder Impacts Around 23.7M People In US, Vistagen Releases Details Around Nasal Spray Treatment Program For It - Mar 30th, 2023 7:18 pm
FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder - Mar 30th, 2023 12:30 pm
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder - Mar 22nd, 2023 12:30 pm
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder - Mar 8th, 2023 1:30 pm
Vistagen to Present at Cowen 43rd Annual Health Care Conference - Mar 2nd, 2023 1:30 pm
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine - Mar 1st, 2023 1:30 pm
VistaGen Shares Plunge Amid Uncertainty Around Its Anxiety Trial - Feb 8th, 2023 5:49 pm
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates - Feb 7th, 2023 11:15 pm
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results - Feb 7th, 2023 9:20 pm
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023 - Feb 6th, 2023 2:09 pm
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition - Feb 2nd, 2023 2:00 pm
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder - Jan 24th, 2023 1:30 pm
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023 - Jan 19th, 2023 1:30 pm
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety - Jan 10th, 2023 1:30 pm